Biotinylated Human TL1A / TNFSF15 Protein, His, Avitag
分子別名（Synonym）
TL1A, VEGI, TNFSF15
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Biotinylated Human TL1A Protein, His,Avitag (TLA-H52Q1) is expressed from human 293 cells (HEK293). It contains AA Leu 72- Leu 251 (Accession # O95150-1).
Predicted N-terminus: His
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 24.1 kDa. The protein migrates as 28-32 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
TNF樣細(xì)胞因子1A（TL1A）及其受體、死亡受體3（DR3）和誘餌受體3（DcR3）分別是TNF和TNF受體蛋白超家族的成員。APC衍生的TL1A與淋巴細(xì)胞DR3的結(jié)合為活化的淋巴細(xì)胞提供了共刺激信號(hào)。DR3信號(hào)不僅影響效應(yīng)淋巴細(xì)胞的增殖活性和細(xì)胞因子的產(chǎn)生，還嚴(yán)重影響調(diào)節(jié)性T細(xì)胞的發(fā)育和抑制功能。然而，DcR3限制了TL1A/DR3復(fù)合物的功能：減弱T細(xì)胞活化并下調(diào)促炎細(xì)胞因子的分泌。與DR3和DcR3一起，TL1A構(gòu)成了一個(gè)細(xì)胞因子系統(tǒng)，積極干擾免疫反應(yīng)的調(diào)節(jié)。
關(guān)鍵字： TL1A;TL1A蛋白;TL1A重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。